A retrospective study on potential drug interactions: A single center experience

Korucu, Fatma Ceyda; Şenyiğit, Ece; Köstek, Osman; Demircan, Nazım Can; Erdoğan, Bülent; Uzunoğlu, Sernaz; Çiçin, İrfan

doi:10.1016/j.jons.2018.06.001

Cited by 5 publications

(7 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, studies that included both pharmacokinetic-and pharmacodynamic-based DDIs and studies that used medication lists from the EHR (rather than those verified by patients during medication reconciliation) had higher rates of potential DDIs. 38,39 Our DDI prevalence of approximately 52% falls in the middle of those reported by past investigations. In terms of methodology, extracting medication data from the EHR and not being able to resolve medication days supply or whether medications were prescribed on an as-needed basis likely resulted in a higher DDI prevalence in our study.…”

Section: Discussionmentioning

confidence: 48%

“…28 advanced cancer, estimating DDIs to occur in 27%-78% of patients. [37][38][39][40][41][42] The large differences in these estimates are likely due to methodological differences among studies. For instance, studies that included both pharmacokinetic-and pharmacodynamic-based DDIs and studies that used medication lists from the EHR (rather than those verified by patients during medication reconciliation) had higher rates of potential DDIs.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Opportunities for Germline Pharmacogenetics and Management of Drug-Drug Interactions in Patients With Advanced Solid Cancers

Shugg

Rowe

et al. 2022

JCO Precision Oncology

View full text Add to dashboard Cite

PURPOSE Precision medicine approaches, including germline pharmacogenetics (PGx) and management of drug-drug interactions (DDIs), are likely to benefit patients with advanced cancer who are frequently prescribed multiple concomitant medications to treat cancer and associated conditions. Our objective was to assess the potential opportunities for PGx and DDI management within a cohort of adults with advanced cancer. METHODS Medication data were collected from the electronic health records for 481 subjects since their first cancer diagnosis. All subjects were genotyped for variants with clinically actionable recommendations in Clinical Pharmacogenetics Implementation Consortium guidelines for 13 pharmacogenes. DDIs were defined as concomitant prescription of strong inhibitors or inducers with sensitive substrates of the same drug-metabolizing enzyme and were assessed for six major cytochrome P450 (CYP) enzymes. RESULTS Approximately 60% of subjects were prescribed at least one medication with Clinical Pharmacogenetics Implementation Consortium recommendations, and approximately 14% of subjects had an instance for actionable PGx, defined as a prescription for a drug in a subject with an actionable genotype. The overall subject-level prevalence of DDIs and serious DDIs were 50.3% and 34.8%, respectively. Serious DDIs were most common for CYP3A, CYP2D6, and CYP2C19, occurring in 24.9%, 16.8%, and 11.7% of subjects, respectively. When assessing PGx and DDIs together, approximately 40% of subjects had at least one opportunity for a precision medicine–based intervention and approximately 98% of subjects had an actionable phenotype for at least one CYP enzyme. CONCLUSION Our findings demonstrate numerous clinical opportunities for germline PGx and DDI management in adults with advanced cancer.

show abstract

Section: Discussionmentioning

confidence: 48%

Section: Discussionmentioning

confidence: 99%

Clinical Opportunities for Germline Pharmacogenetics and Management of Drug-Drug Interactions in Patients With Advanced Solid Cancers

Shugg

Rowe

et al. 2022

JCO Precision Oncology

View full text Add to dashboard Cite

show abstract

“…However, strong CYP3A4 iso-enzyme inhibitors, such as itraconazole, can increase the plasma concentrations and pharmacologic effects of fentanyl, due to this CYP3A4 inhibitor's potential reduction in the metabolic clearance of this opioid. More examples may follow, as bicalutamide and dexamethasone, which also affect the CYP3A4 enzyme, can increase or decrease (respectively) the level or effect of fentanyl [52]. Therefore, it is necessary to watch for the cumulative narcotic effects of fentanyl when this drug is administered with another chemotherapeutics.…”

Section: Effect On Cancer Treatmentmentioning

confidence: 99%

Personalized Medicine for Classical Anesthesia Drugs and Cancer Progression

Costa

Mourão

Vale

2022

JPM

View full text Add to dashboard Cite

In this review, we aim to discuss the use and effect of five different drugs used in the induction of anesthesia in cancer patients. Propofol, fentanyl, rocuronium, sugammadex, and dexamethasone are commonly used to induce anesthesia and prevent pain during surgery. Currently, the mechanisms of these drugs to induce the state of anesthesia are not yet fully understood, despite their use being considered safe. An association between anesthetic agents and cancer progression has been determined; therefore, it is essential to recognize the effects of all agents during cancer treatment and to evaluate whether the treatment provided to the patients could be more precise. We also highlight the use of in silico tools to review drug interaction effects and safety, as well as the efficacy of the treatment used according to different subgroups of patients.

show abstract

“… 7 Drug interactions are either real drug interactions that can be established in clinical practice or potential drug–drug interactions (PDDIs) in which a potentially harmful combination occurs. 8 …”

Section: Introductionmentioning

confidence: 99%

“…7 Drug interactions are either real drug interactions that can be established in clinical practice or potential drug-drug interactions (PDDIs) in which a potentially harmful combination occurs. 8 The consequences of these DDIs vary, from minor and undetectable to severe enough that can affect the patient's health, increase the treatment costs, or even can lead to death. 9 There are many factors associated with the occurrence of DDIs, and one of them is the use of multiple drug treatments, which might be necessary to achieve the required therapeutic goal.…”

Section: Introductionmentioning

confidence: 99%

The Prevalence and Severity of Potential Drug–Drug Interactions in Internal Medicine Ward at Soba Teaching Hospital

Hamadouk,

Alshareif,

Hamad

et al. 2023

DHPS

View full text Add to dashboard Cite

Background Multiple drug therapies are commonly used to achieve a desired therapeutic goal, especially in hospitalized patients. However, drug–drug interactions might occur and threaten the patients’ safety. Objective This study aims to assess the prevalence and severity of potential drug–drug interactions (PDDIs) in the internal medicine ward at Soba Teaching Hospital. Methods A retrospective cross-sectional hospital-based study was carried out in the internal medicine ward at Soba Teaching Hospital from June 2021 to December 2021. The data was collected from patients’ medical records. PDDIs were identified using Lexicomp ® drug interaction software. Results A total of 377 patients were included in this study, and overall prevalence of PDDIs was 62.9%. We have identified 989 potential DDIs and 345 pairs of interacting drugs, the mean of the PDDIs per patient was 4.17 ± 4.079. Among 345 PDDIs most were of moderate interactions 70.1% (n=242) followed by Minor interactions 19.1% (n=66). The most common type of interaction was of category C representing 63.5% (n=219). A significant association was observed between the occurrence of PDDIs with patients’ age, presence of chronic diseases, length of hospital stay, and number of medications received by the patients. Conclusion Drug–drug interactions were highly prevalent in the internal medicine ward. Therefore, certain attempts are required to increase the awareness of the physicians about these interactions and minimize their occurrence.

show abstract

A retrospective study on potential drug interactions: A single center experience

Cited by 5 publications

References 24 publications

Clinical Opportunities for Germline Pharmacogenetics and Management of Drug-Drug Interactions in Patients With Advanced Solid Cancers

Clinical Opportunities for Germline Pharmacogenetics and Management of Drug-Drug Interactions in Patients With Advanced Solid Cancers

Personalized Medicine for Classical Anesthesia Drugs and Cancer Progression

The Prevalence and Severity of Potential Drug–Drug Interactions in Internal Medicine Ward at Soba Teaching Hospital

Contact Info

Product

Resources

About